Hemostemix names Dr. Desirée Cox to board

By AI, Created 2:55 PM UTC, May 25, 2026, /AGP/ – Hemostemix has appointed Dr. Desirée Cox to its board of directors as the company advances commercialization of ACP-01, also known as VesCell™, in The Bahamas. The move adds a veteran of regenerative medicine ethics and policy as Hemostemix pushes treatments for vascular and ischemic conditions.

Why it matters: - Hemostemix is trying to turn ACP-01, or VesCell™, into a commercial treatment in The Bahamas. - Dr. Desirée Cox brings experience in regenerative medicine ethics, governance and health policy. - The appointment comes as Hemostemix works on a commercial Phase I clinical trial using a basket protocol approach.

What happened: - Hemostemix appointed Dr. Desirée Cox to its board of directors on May 25, 2026. - The company said the hire supports its push to commercialize ACP-01 in The Bahamas. - Hemostemix described ACP-01 as a treatment for peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy and vascular dementia.

The details: - Hemostemix operates as an autologous stem cell company focused on VesCell™ commercialization. - Dr. Cox is a physician, scientist, philosopher, bioethicist, quantum chemist and artist. - She has worked in regenerative medicine ethics and governance in The Bahamas for more than a decade. - Dr. Cox previously chaired the National Stem Cell Ethics Committee in The Bahamas. - She helped develop the ethical and legislative framework behind The Bahamas’ Longevity and Regenerative Therapies Act, or LARTA. - Hemostemix said LARTA was designed to make The Bahamas a global center for regenerative medicine, longevity sciences and responsible clinical innovation. - Dr. Cox is the founder of HEALinc, a global health innovation platform focused on whole-person health and access to regenerative longevity technologies, products and services. - Her academic background includes McGill University, the University of Oxford and the University of Cambridge. - Hemostemix said Dr. Cox is a Rhodes Scholar.

Between the lines: - The board appointment appears aimed at strengthening Hemostemix’s credibility around ethics, regulation and commercialization in a sensitive therapeutic area. - The company is signaling that The Bahamas remains central to its strategy for clinical access and market development. - Dr. Cox’s comments frame regenerative medicine as a long-term shift in healthcare and position Hemostemix as part of that transition.

What’s next: - Hemostemix said it will continue commercializing ACP-01 in The Bahamas. - The company also said it will keep advancing the commercial Phase I trial. - Forward-looking statements in the release say the company is pursuing sales of VesCell™ treatments in The Bahamas, but outcomes are not guaranteed.

The bottom line: - Hemostemix is adding an ethics and policy veteran to its board as it tries to move a stem cell therapy from clinical development toward commercialization.